Sarepta Therapeutics, Inc. Q3 2021 Earnings Conference Call
Forward Looking Statements

Wednesday, November 3, 2021 – 4:30 p.m. Eastern Time

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities, research and development programs, and the potential benefits of our product candidates, including the potentially transformative benefits of SRP-9001; the potential for our PPMO and RNA platforms to treat as many as 80% of individuals living with Duchenne; the potential for our PMO-based exon skipping therapies to benefit nearly 30% of individuals living with Duchenne; our belief that the exon 45 skip amenable patient population may be larger than the 53 skip amenable population; the potential for SRP-5051 to offer individuals living with Duchenne a more convenient once-per-month treatment option with a manageable safety profile and potentially greater than 10% dystrophin with once-per-month dosing over time; our belief, based on discussions with U.S. and European regulators, that using beta-sarcoglycan protein expression may be sufficient for accelerated and conditional approval, respectively; our belief that hypomagnesemia is monitorable and manageable with prophylactic magnesium supplements and is not correlated with changes in renal function for SRP-5051; the potential benefits of our rh74 capsid; the potential of our EMBARK study to confirm that SRP-9001 commercially representative material confers clinical functional benefit in 4 to 7 year old boys; our potential to adapt and execute on any potential scenario that comes our way in the coming months and years; and expected plans and milestones, including our plan to fund our multi-platform pipeline, including moving our 6-program LGMD portfolio forward, our plan to explore a potential platform trial for LGMD to simultaneously address our three sarcoglycan programs, covering LGMD types 2E, 2C and 2D, announcing results from Part 2 of Study 9001-102 in the first quarter of 2022, completing CMC work for commercially representative SRP-9003 material in 2022, continuing discussions with agencies for SRP-9003 and designing a pivotal trial, our plan for Part B of MOMENTUM to serve as our pivotal trial for SRP-5051, our plan to continue to build our Gene Editing Innovation Center in Durham, North Carolina, focused on the advancement of CRSPR/CAS9, and fully enrolling Study SRP-9001-301 in the first half of 2022.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to sales of our products or attain the anticipated net revenues, profitability or positive cash-flow from operations; we may not be able to comply with all FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; our dependence on certain manufacturers to produce our products and product candidates, including any inability on our part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; our data for SRP-5051, SRP-9001, the LGMD programs and/or other programs may not be sufficient for obtaining regulatory approval; success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; the commencement and completion of our clinical trials and announcement of results may be delayed or prevented for a number of reasons, including, among others, denial by the regulatory agencies of permission to proceed with our clinical trials, or placement of a clinical trial on hold, challenges in identifying, recruiting, enrolling and retaining patients to participate in clinical trials and inadequate quantity or quality of supplies of a product candidate or other materials necessary to conduct clinical trials; if the actual number of patients living with the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, many of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the ongoing COVID-19 pandemic; and those risks identified under the heading "Risk Factors" in our most recent Annual Report on Form 10-K for the year ended December 31, 2020 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.